Clinical trial · Observational
Clinical Significance of Marginal Acute Inflammation for Stage II Colon Cancer
Presence and Clinical Significance of Marginal Acute Inflammation for Stage II Colon Cancer
NCT06135558CI-TRIAL-00071516completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Marginal acute inflammation would make reporting the serosal involvement of tumors controversial. We aimed to investigate the clinical significance and explore the prognostic value of MAI for stage II localized colon cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
| Inflammation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MAI detection | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- T3
- description
- patient staged T3 without marginal acute inflammation
- interventionNames
- Diagnostic Test: MAI detection
- label
- MAI
- description
- patient with marginal acute inflammation
- interventionNames
- Diagnostic Test: MAI detection
- label
- T4
- description
- patient staged T4 without marginal acute inflammation
- interventionNames
- Diagnostic Test: MAI detection
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * (1) colon cancer patients with the preoperative staging of stage I-III who lacked distant metastasis; (2) patients who underwent radical resection, with postoperative pathology confirmed as pT3-4N0M0; and (3) complete follow-up information Exclusion Criteria: * (1) patients who received neo-adjuvant therapy; (2) patients with multiple primary colorectal cancer; and (3) patients with a history of malignant tumors
References
Publications (0)
Data not yet available
No reference posted for this study.